Historical Valuation
Gyre Therapeutics Inc (GYRE) is now in the Undervalued zone, suggesting that its current forward PS ratio of 4.17 is considered Undervalued compared with the five-year average of 11.97. The fair price of Gyre Therapeutics Inc (GYRE) is between 19.91 to 27.45 according to relative valuation methord. Compared to the current price of 7.57 USD , Gyre Therapeutics Inc is Undervalued By 61.97%.
Relative Value
Fair Zone
19.91-27.45
Current Price：7.57
61.97%
Undervalued
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
Gyre Therapeutics Inc (GYRE) has a current Price-to-Book (P/B) ratio of 6.07. Compared to its 3-year average P/B ratio of -5.39 , the current P/B ratio is approximately -212.65% higher. Relative to its 5-year average P/B ratio of -5.39, the current P/B ratio is about -212.65% higher. Gyre Therapeutics Inc (GYRE) has a Forward Free Cash Flow (FCF) yield of approximately 0.47%. Compared to its 3-year average FCF yield of 0.05%, the current FCF yield is approximately 894.98% lower. Relative to its 5-year average FCF yield of 0.05% , the current FCF yield is about 894.98% lower.
P/B
Median3y
-5.39
Median5y
-5.39
FCF Yield
Median3y
0.05
Median5y
0.05
Competitors Valuation Multiple
AI Analysis for GYRE
The average P/S ratio for GYRE competitors is 45.52, providing a benchmark for relative valuation. Gyre Therapeutics Inc Corp (GYRE.O) exhibits a P/S ratio of 4.17, which is -90.84% above the industry average. Given its robust revenue growth of 19.92%, this premium appears unsustainable.
Performance Decomposition
AI Analysis for GYRE
1Y
3Y
5Y
Market capitalization of GYRE increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of GYRE in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is GYRE currently overvalued or undervalued?
Gyre Therapeutics Inc (GYRE) is now in the Undervalued zone, suggesting that its current forward PS ratio of 4.17 is considered Undervalued compared with the five-year average of 11.97. The fair price of Gyre Therapeutics Inc (GYRE) is between 19.91 to 27.45 according to relative valuation methord. Compared to the current price of 7.57 USD , Gyre Therapeutics Inc is Undervalued By 61.97% .
What is Gyre Therapeutics Inc (GYRE) fair value?
GYRE's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Gyre Therapeutics Inc (GYRE) is between 19.91 to 27.45 according to relative valuation methord.
How does GYRE's valuation metrics compare to the industry average?
The average P/S ratio for GYRE's competitors is 45.52, providing a benchmark for relative valuation. Gyre Therapeutics Inc Corp (GYRE) exhibits a P/S ratio of 4.17, which is -90.84% above the industry average. Given its robust revenue growth of 19.92%, this premium appears unsustainable.
What is the current P/B ratio for Gyre Therapeutics Inc (GYRE) as of Jan 09 2026?
As of Jan 09 2026, Gyre Therapeutics Inc (GYRE) has a P/B ratio of 6.07. This indicates that the market values GYRE at 6.07 times its book value.
What is the current FCF Yield for Gyre Therapeutics Inc (GYRE) as of Jan 09 2026?
As of Jan 09 2026, Gyre Therapeutics Inc (GYRE) has a FCF Yield of 0.47%. This means that for every dollar of Gyre Therapeutics Inc’s market capitalization, the company generates 0.47 cents in free cash flow.
What is the current Forward P/E ratio for Gyre Therapeutics Inc (GYRE) as of Jan 09 2026?
As of Jan 09 2026, Gyre Therapeutics Inc (GYRE) has a Forward P/E ratio of 31.67. This means the market is willing to pay $31.67 for every dollar of Gyre Therapeutics Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Gyre Therapeutics Inc (GYRE) as of Jan 09 2026?
As of Jan 09 2026, Gyre Therapeutics Inc (GYRE) has a Forward P/S ratio of 4.17. This means the market is valuing GYRE at $4.17 for every dollar of expected revenue over the next 12 months.